First pivotal, randomized, blinded placebo-controlled trial of Naronapride for treatment of GI motility disorders.
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Naronapride (Primary)
- Indications Gastrointestinal motility disorders
- Focus Adverse reactions; Registrational
- 01 Dec 2016 New trial record
- 16 Nov 2016 According to a Renexxion media release, company has received positive guidance on the design of this trial, required for NDA filing for naronapride by U. S. FDA.